Artelo Biosciences (NASDAQ:ARTL) is expanding its development pipeline into ophthalmology with a new clinical study evaluating its drug candidate ART27.13 for the treatment of glaucoma. The San ...

Looking back, glaucoma specialists like Dr. Christine Funke of Barnet Dulaney Perkins Eye Center can remember a time not long ago when treatment options for the eye condition were greatly limited.

Artelo Biosciences (NASDAQ: ARTL) has announced its entry into the ophthalmology space with a fully funded clinical study evaluating ART27.13 in glaucoma patients. The investigator-sponsored trial ...

Investigator-sponsored study funded by Glaucoma UK and the HSC R&D Division expands ART27.13’s clinical potential into ophthalmologyFirst ...

Explore the latest research on glaucoma treatment and the role of immune cells in eye pressure regulation for better outcomes ...

Please provide your email address to receive an email when new articles are posted on . Before the introduction of OCT, the standard of care for identifying initial glaucomatous damage was based on ...

Glaucoma, caused by high pressure within the eye, affects some 2.5 million Americans and is the nation's second leading cause of blindness. Optometrists screen for it during routine eye exams, often ...

Please provide your email address to receive an email when new articles are posted on . Consider angle morphology when treating patients with neovascular glaucoma. Comparable visual acuity and IOP and ...

Markers in the blood that predict whether glaucoma patients are at higher risk of continued loss of vision following conventional treatment have been identified by researchers. Markers in the blood ...

Glaucoma is both preventable, with early treatment, and the leading cause of blindness in those over 60. Additionally, the incidence of glaucoma and its harms are greater in both our Black and ...

Glaucoma can silently damage your optic nerve, leading to irreversible vision loss. Learn the early signs, risk factors, and ...